Log In
BCIQ
Print this Print this
 

F001287

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionSmall molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)
Molecular Target Indoleamine 2,3-dioxygenase 1 (IDO1)
Mechanism of ActionIndoleamine 2,3-dioxygenase (INDO) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,250.0M

$800.0M

$450.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/08/2015

$1,250.0M

$800.0M

$450.0M

Get a free BioCentury trial today